We are live on
!
Find out more
Primecap Management Portfolio holdings
AUM
$169B
Turnover
4.85%
1-Year Est. Return
114.72%
This Fund
S&P 500
This Quarter
Est. Return
+8.4%
1 Year Est. Return
+114.72%
3 Year Est. Return
+234.44%
5 Year Est. Return
+291.25%
10 Year Est. Return
+1,263.36%
AUM
$149B
AUM Growth
+$5.43B
(+3.8%)
Cap. Flow
-$4.27B
Cap. Flow
% of AUM
-2.87%
Top 10 Holdings %
Top 10 Hldgs %
30.32%
Holding
338
New
11
Increased
51
Reduced
229
Closed
5
Avg Time Held
4.7
years
Top 10 Avg Time Held
5
years
Top 20 Avg Time Held
4.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Splunk Inc
SPLK
|
+$151M |
| 2 |
Alibaba
BABA
|
+$115M |
| 3 |
XPeng
XPEV
|
+$79M |
| 4 |
Raymond James Financial
RJF
|
+$71.4M |
| 5 |
Allogene Therapeutics
ALLO
|
+$64.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$285M |
| 2 |
NetApp
NTAP
|
+$236M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$220M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$209M |
| 5 |
Adobe
ADBE
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.47% |
| 2 | Healthcare | 26.99% |
| 3 | Industrials | 12.32% |
| 4 | Consumer Discretionary | 10.96% |
| 5 | Financials | 10.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
201
Axon Enterprise
AXON
$32.4B
| $46.3M | 0.03% |
262,000
-9,700
| -4% | -$1.43M |
2016 Q2
20 quarters
|
|
202
DELISTED
GAN Ltd
GAN
| $45.5M | 0.03% |
2,769,532
+1,686,332
| +156% | +$29.7M |
2020 Q2
4 quarters
|
|
203
XPO
XPO
$22B
| $45.4M | 0.03% |
937,679
+124,330
| +15% | +$6.07M |
2021 Q1
1 quarter
|
|
204
nLIGHT
LASR
$1.96B
| $43.1M | 0.03% |
1,187,524
+6,650
| +0.6% | +$199K |
2018 Q2
12 quarters
|
|
|
TPTX
205
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $40.7M | 0.03% |
521,560
+55,320
| +12% | +$4.09M |
2020 Q2
4 quarters
|
|
206
Merck
MRK
$362B
| $40.5M | 0.03% |
520,700
-706,927
| -58% | -$52.6M |
2014 Q4
26 quarters
|
|
207
BJs Wholesale Club
BJ
$12.8B
| $40.2M | 0.03% |
845,700
-340
| -0% | -$15.6K |
2019 Q2
8 quarters
|
|
208
OSI Systems
OSIS
$3.09B
| $38.6M | 0.03% |
379,950
-2,900
| -0.8% | -$282K |
2016 Q1
21 quarters
|
|
209
Glaukos
GKOS
$9.71B
| $37.7M | 0.03% |
444,500
+8,200
| +2% | +$673K |
2017 Q4
14 quarters
|
|
210
Arlo Technologies
ARLO
$1.31B
| $36.8M | 0.02% |
5,435,270
+555,830
| +11% | +$3.62M |
2018 Q3
11 quarters
|
|
211
MGM Resorts International
MGM
$7.3B
| $36.5M | 0.02% |
856,450
-450
| -0.1% | -$18.6K |
2016 Q3
19 quarters
|
|
212
DoorDash
DASH
$82.9B
| $36.1M | 0.02% |
202,620
-13,960
| -6% | -$2.05M |
2020 Q4
2 quarters
|
|
213
Sphere Entertainment
SPHR
$3.78B
| $35.9M | 0.02% |
427,001
+211,128
| +98% | +$18.7M |
2020 Q2
4 quarters
|
|
|
MAXR
214
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
| $35.8M | 0.02% |
897,240
+82,840
| +10% | +$2.95M |
2018 Q2
12 quarters
|
|
215
Ambarella
AMBA
$2.71B
| $33.9M | 0.02% |
318,200
+22,200
| +8% | +$2.2M |
2020 Q3
3 quarters
|
|
|
ARNA
216
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $33.9M | 0.02% |
496,800
-7,290
| -1% | -$475K |
2018 Q3
11 quarters
|
|
217
Standard BioTools
LAB
$252M
| $32.9M | 0.02% |
5,342,153
-78,590
| -1% | -$420K |
2013 Q2
32 quarters
|
|
218
Salesforce
CRM
$197B
| $31.8M | 0.02% |
130,000
| – | – |
2013 Q2
32 quarters
|
|
219
Norfolk Southern
NSC
$72.8B
| $31.1M | 0.02% |
117,100
-1,400
| -1% | -$386K |
2013 Q2
32 quarters
|
|
220
Wave Life Sciences
WVE
$615M
| $30.6M | 0.02% |
4,587,566
-78,384
| -2% | -$512K |
2019 Q3
7 quarters
|
|
221
Tyson Foods
TSN
$19.3B
| $30.5M | 0.02% |
413,300
-2,600
| -0.6% | -$202K |
2014 Q4
26 quarters
|
|
222
IMAX
IMAX
$2.81B
| $29.8M | 0.02% |
1,384,900
-240,512
| -15% | -$5.18M |
2016 Q1
21 quarters
|
|
223
Optimum Communications Inc
OPTU
$353M
| $28.6M | 0.02% |
836,800
| – | – |
2020 Q1
5 quarters
|
|
224
Gibraltar Industries
ROCK
$1.14B
| $28.4M | 0.02% |
372,100
-2,800
| -0.7% | -$231K |
2017 Q4
14 quarters
|
|
225
Enovis
ENOV
$1.13B
| $28.1M | 0.02% |
355,921
-1,162
| -0.3% | -$89K |
2019 Q3
7 quarters
|
|
Similar funds
Primecap Management's Q2 2021 Portfolio in Review
As of Q2 2021, Primecap Management held 338 positions worth $149B, up 3.8% from $143B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Trading was light in Q2 2021: portfolio turnover was 4.7%. Primecap Management opened 11 new positions and exited 5, leaving the 338-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 31% a quarter earlier, followed by Healthcare and Industrials.
- Primecap Management's largest Q2 2021 buy was Xometry: 300,000 shares worth $26.2M.
- Primecap Management added most to Splunk Inc in Q2 2021, an estimated $151M increase.
- Primecap Management's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $285M.
- Primecap Management fully exited Perspecta Inc. Common Stock in Q2 2021, selling an estimated $16.9M.
- Primecap Management's ten largest holdings make up 30% of its $149B portfolio in Q2 2021.
- Primecap Management opened 11 new positions and closed 5 in Q2 2021.
- Primecap Management's portfolio value rose 3.8% quarter-over-quarter to $149B.
Based on Primecap Management's 13F filing for Q2 2021, filed 10 Aug 2021.